PRGO vs. CORT, SUPN, PCRX, JAZZ, ALKS, AXSM, ALPN, INSM, NUVL, and HCM
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), Axsome Therapeutics (AXSM), Alpine Immune Sciences (ALPN), Insmed (INSM), Nuvalent (NUVL), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Perrigo has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Perrigo currently has a consensus price target of $40.67, indicating a potential upside of 48.80%. Corcept Therapeutics has a consensus price target of $40.10, indicating a potential upside of 29.19%. Given Perrigo's higher probable upside, equities analysts clearly believe Perrigo is more favorable than Corcept Therapeutics.
95.9% of Perrigo shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Perrigo received 239 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.62% of users gave Corcept Therapeutics an outperform vote while only 66.75% of users gave Perrigo an outperform vote.
Corcept Therapeutics has a net margin of 22.38% compared to Perrigo's net margin of -0.17%. Corcept Therapeutics' return on equity of 24.19% beat Perrigo's return on equity.
In the previous week, Corcept Therapeutics had 6 more articles in the media than Perrigo. MarketBeat recorded 12 mentions for Corcept Therapeutics and 6 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.03 beat Perrigo's score of 0.74 indicating that Corcept Therapeutics is being referred to more favorably in the news media.
Summary
Corcept Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
